公开(公告)号：US11555069B2

公开(公告)日：2023-01-17

申请号：US16471718

申请日：2017-12-26

申请人： Kao Corporation

发明人： Fumiaki Okahara ,  Yoshitaka Koga ,  Takuya Mori

IPC分类号： C07K16/26 ,  A61K31/166 ,  A61K31/201 ,  A61K31/215 ,  A61K31/404 ,  A61K31/519 ,  A61K31/683 ,  A61K31/717 ,  A61K31/718 ,  A61K31/722 ,  A61K31/734 ,  A61K31/785 ,  A61K36/07 ,  A61K36/185

摘要： Provided are a cognitive function improving agent effective for improving cognitive function such as memory and learning ability, and a method for evaluating or selecting the cognitive function improving agent. The cognitive function improving agent comprises a GIP function inhibitor as an active ingredient.

公开(公告)号：US20220387371A1

公开(公告)日：2022-12-08

申请号：US17888115

申请日：2022-08-15

申请人： Vifor (International) AG

发明人： Peter Geisser ,  Erik Philipp ,  Walter Richle

IPC分类号： A61K31/295 ,  A61P7/06 ,  A61K31/718 ,  A61K33/26 ,  A61K45/06 ,  C08B31/18 ,  A61K47/61 ,  C08B30/18 ,  C08B37/00

摘要： A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.

公开(公告)号：US20220226400A1

公开(公告)日：2022-07-21

申请号：US17613852

申请日：2020-04-22

申请人： McPharma Biotech Inc.

发明人： Derek McLaren ,  Earl McLaren

IPC分类号： A61K35/747 ,  C12Q1/689 ,  C12Q1/6869 ,  A61K31/718 ,  A61K31/736 ,  A61K31/198 ,  A61K35/745 ,  A61K35/741 ,  A61K35/742 ,  A61K31/702 ,  A61P3/06

摘要： Elucidating the relationship between specific intestinal bacteria, dietary intake, and the health of the host remains a primary goal for gut microbiome research. Prebiotics, substrates that are selectively used by microorganisms to promote the health of the host, present an appealing therapeutic option. We performed correlation analysis to identify relationships between health parameters and populations of gut bacteria in participants from a randomized, placebo-controlled clinical trial testing the effects of a prebiotic digestion resistant potato starch (DRS; MSPrebiotic®). This study focused on the abundance of Parasutterella (phylum Proteobacteria), which tended to increase in the gut microbiome of individuals consuming DRS. Increases in Parasutterella were correlated with reductions in low-density lipoprotein (LDL) levels in participants consuming DRS but not placebo. Segregating DRS-consuming individuals based on whether LDL levels decreased revealed that DRS-consuming individuals who displayed improved LDL levels had significantly higher baseline levels of Parasutterella. Taken together, our analyses suggest that DRS may help improve LDL levels depending on the initial ecological composition of an individual's gut microbiome.

公开(公告)号：US20220218002A1

公开(公告)日：2022-07-14

申请号：US17650242

申请日：2022-02-07

申请人： Mark D. Holt

发明人： Mark D. Holt

IPC分类号： A23K50/10 ,  A23K20/163 ,  A23K20/147 ,  A23K40/20 ,  A61K31/718 ,  A23K40/25 ,  A61K9/00

摘要： Method of producing a feedstuff for a dairy animal that potentiates milk production. The method includes a multi-stage process having one stage in which a feed grain for dairy animals is heat-treated for a period of time at a temperature above 90 degrees Celsius. The grain is processed for another period of time that includes disrupting the prolamin/protein bonds which produces a hydrophilic, vitreous feedstuff having a starch and protein matrix composed at least partially by prolamin. The feed grain is heat-treated for a first period of time, of which at least 200 seconds is maintained above 90 degrees Celsius, and thereafter the feed grain is processed in a second stage by applying sufficient processing to disrupt the prolamin/protein bonds and thereby producing a hydrophilic, vitreous, feedstuff comprising a starch and protein matrix composed of at least three percent prolamin.

公开(公告)号：US11253569B2

公开(公告)日：2022-02-22

申请号：US16401698

申请日：2019-05-02

申请人： Seattle Children's Hospital

发明人： Michael A. Portman

IPC分类号： A61K38/17 ,  A61P17/00 ,  C07K16/06 ,  C07K16/24 ,  A61K39/395 ,  A61K31/047 ,  A61K31/7016 ,  A61K31/717 ,  A61K31/718 ,  A61K31/25 ,  A61K31/05 ,  A61K47/18 ,  A61K47/36 ,  A61K47/02 ,  A61K47/12 ,  A61K31/60 ,  A61K31/192 ,  A61K9/00

摘要： The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.

公开(公告)号：US20210361696A1

公开(公告)日：2021-11-25

申请号：US16771573

申请日：2017-06-16

申请人： Boris Farber ,  Sof'ya Farber ,  ARTUR VIKTOROVICH MARTYNOV

发明人： Boris Farber ,  Sof'ya Farber ,  ARTUR VIKTOROVICH MARTYNOV

IPC分类号： A61K31/727 ,  A61K31/717 ,  A61K31/722 ,  A61K31/718 ,  A61P37/02 ,  A61P31/12 ,  A61P17/02 ,  A61P7/04

摘要： The invention related to organic and bioorganic combinatorial chemistry, namely, to new combinatorial libraries of polysaccharide derivatives and supramolecular structures based on them, which, when used without separation into separate components, have high biological activity.
The essence is a combinatorial library and a supramolecular structure based on it from biologically active derivatives of polysaccharides, as well as pharmaceutical compositions based on them with a hemostatic, wound healing, antiviral and immunomodulating action, containing as an active substance an undivided whole combinatorial mixture of substituted glucopyranose polymer derivatives, obtained simultaneous combinatorial modification of a polysaccharide with at least two covalent modifier in the synthesis, a combinatorial mixture with the maximum number of combinations of modified polysaccharide derivatives is formed, and as a biologically active substance, a whole combinatorial mixture of polysaccharide derivatives in the form of a supramolecular structure without separation into individual components is used to obtain a pharmaceutical composition.

公开(公告)号：US11058711B2

公开(公告)日：2021-07-13

申请号：US16301517

申请日：2017-07-06

申请人： McPharma Biotech Inc.

发明人： Derek McLaren ,  Earl McLaren

IPC分类号： A61K31/718 ,  A61K35/745 ,  A61P1/14 ,  C08L3/02 ,  A23L33/105 ,  A23L33/135 ,  A61K36/81

摘要： Consumption of resistant potato starch results in changes to the gut microbiome in elderly adults, resulting in a healthier gut microbiome profile. Furthermore, consumption of resistant potato starch stimulates an increase in Bifidobacterium abundance in all individuals and also reduces levels of E. coli and Shigella. Furthermore, consumption of MSPrebiotic® increased the relative ratio of butyrate in the elderly and significantly reduced the use of stool softeners in the elderly.

公开(公告)号：US11000531B2

公开(公告)日：2021-05-11

申请号：US16829661

申请日：2020-03-25

申请人： MARINUS PHARMACEUTICALS INC.

发明人： Christopher Cashman ,  Jaakko Lappalainen ,  David A. Czekai

IPC分类号： A61K31/57 ,  A61K31/565 ,  A61K31/573 ,  C07J7/00 ,  A61K45/06 ,  A61K31/5513 ,  A61K47/36 ,  A61K47/69 ,  A61K47/32 ,  A61K47/10 ,  A61K9/00 ,  C08B37/16 ,  A61K47/38 ,  A61K9/107 ,  A61K31/718 ,  A61K31/721

摘要： The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.

公开(公告)号：US20210077546A1

公开(公告)日：2021-03-18

申请号：US16642557

申请日：2018-08-29

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Thomas M. SCHMIDT ,  Nielson BAXTER ,  Kwi KIM ,  Alexander SCHMIDT ,  Arvind VENKATARAMAN ,  Clive WALDRON

IPC分类号： A61K35/745 ,  A61K31/718 ,  A61K9/48 ,  A61K9/00 ,  A61K35/742 ,  A61P1/00

摘要： Provided herein are compositions and methods for increasing butyrate production in a subject. In particular, provided herein are compositions, probiotic compositions, and combinations thereof that promote butyrate production in a subject.

公开(公告)号：US20200206259A1

公开(公告)日：2020-07-02

申请号：US16473168

申请日：2017-12-22

申请人： EZAKI GLICO, CO., LTD.

发明人： Hiroshi Watanabe ,  Yoshinobu Terada

IPC分类号： A61K31/718 ,  C12P19/04 ,  C12P19/22 ,  C12P19/20 ,  A61K9/00 ,  A61P3/10 ,  C08B30/18 ,  A23L33/125 ,  A23L2/52

摘要： One purpose of the present invention is to provide a high molecular weight glucan having both properties low digestion rate and high digestibility. A high molecular weight glucan that has property digested slowly and contains almost no indigestible ingredients is produced by enzymatic reactions of (1) a specific concentration of branching enzyme and (2) 4-α-glucanotransferase and/or an exo-type amylase to a branched glucan used as a substrate.